GGrantIndex
← Leaderboards

James W Mier

Brigham And Women'S Hospital

$3,282,868
Attributed
$3,282,868
Total exposure
8
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $474.4K · FY200519
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$3,282,868 · 8

By mechanism

P50$2,919,126 · 5
R21$306,000 · 1
M01$57,742 · 2

Top collaborators

No co-investigators on record.

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsPharmaceutical PreparationsTumorInhibitor/AntagonistDrug DevelopmentCellsSignal TransductionResponseNeoplastic CellBaseEventProteinsBay 54-9085MelanomaIn VivoCell GrowthMitogen-Activated Protein KinasesPathway InteractionsApoptosisMolecularAngiogenesisGrantCell LineCell Survival

Grant awards (19)

Small Molecule HIF2a Inhibitors for Treatment of Renal Cell Carcinoma$270,183
P50 · FY2019 · CA · contact PI
HDM2 as a Therapeutic Target in RCC$236,861
P50 · FY2018 · CA · contact PI
HDM2 as a Therapeutic Target in RCC$237,240
P50 · FY2017 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$140,848
P50 · FY2013 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$259,801
P50 · FY2012 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$147,424
P50 · FY2012 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$294,646
P50 · FY2011 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$139,982
P50 · FY2011 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$326,994
P50 · FY2010 · CA · contact PI
P4 - Treating the P13-Kinase/AKT$147,443
P50 · FY2010 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$320,636
P50 · FY2009 · CA · contact PI
Treating the P13-Kinase/AKT$147,910
P50 · FY2009 · CA · contact PI
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for$249,158
P50 · FY2008 · CA · contact PI
PHASE I CLINICAL TRIAL OF DECITABINE PRIOR TO DACARBAZINE IN ADVANCED MELANOMA$9,049
M01 · FY2006 · RR · contact PI
PHASE I CLINICAL TRIAL OF DECITABINE PRIOR TO DACARBAZINE IN ADVANCED MELANOMA$48,693
M01 · FY2005 · RR
Clinical Trials with IL12$153,000
R21 · FY2002 · CA
CORE--IMMUNE MONITORING$0
P50 · FY2002 · CA
Clinical Trials with IL12$153,000
R21 · FY2001 · CA
CORE--IMMUNE MONITORING$0
P50 · FY2001 · CA